Cambrex (CBM) Receiving Somewhat Favorable News Coverage, Study Shows

Headlines about Cambrex (NYSE:CBM) have trended somewhat positive recently, Accern Sentiment reports. The research group scores the sentiment of news coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Cambrex earned a daily sentiment score of 0.16 on Accern’s scale. Accern also assigned press coverage about the biotechnology company an impact score of 46.699062917973 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.

Separately, Craig Hallum restated a “buy” rating and issued a $60.00 price objective (down from $70.00) on shares of Cambrex in a report on Tuesday, October 31st. One investment analyst has rated the stock with a sell rating, two have given a hold rating and three have issued a buy rating to the stock. Cambrex currently has a consensus rating of “Hold” and a consensus target price of $62.33.

Shares of Cambrex (NYSE CBM) traded down $0.15 during midday trading on Friday, hitting $51.65. 151,200 shares of the company’s stock were exchanged, compared to its average volume of 326,399. The company has a market capitalization of $1,690.00, a P/E ratio of 16.93, a price-to-earnings-growth ratio of 1.25 and a beta of 2.26. Cambrex has a fifty-two week low of $42.55 and a fifty-two week high of $62.95.

Cambrex (NYSE:CBM) last announced its quarterly earnings results on Tuesday, November 7th. The biotechnology company reported $0.55 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.47 by $0.08. The company had revenue of $112.60 million during the quarter, compared to the consensus estimate of $108.44 million. Cambrex had a net margin of 18.79% and a return on equity of 23.42%. The firm’s quarterly revenue was up 13.4% compared to the same quarter last year. During the same quarter last year, the firm earned $0.47 earnings per share. equities research analysts anticipate that Cambrex will post 2.97 earnings per share for the current year.

TRADEMARK VIOLATION NOTICE: This piece of content was published by The Lincolnian Online and is owned by of The Lincolnian Online. If you are reading this piece of content on another site, it was stolen and reposted in violation of U.S. & international trademark & copyright legislation. The legal version of this piece of content can be viewed at https://www.thelincolnianonline.com/2018/01/13/somewhat-favorable-news-coverage-somewhat-unlikely-to-affect-cambrex-cbm-stock-price-updated-updated.html.

Cambrex Company Profile

Cambrex Corporation (Cambrex) is a life sciences company. It provides products and services for the development and commercialization of generic therapeutics. It operates through four segments, which are manufacturing facilities that have been aggregated as a single segment. Its manufacturing facilities are owned by the subsidiaries, including Cambrex Charles City, Inc, Cambrex Karlskoga AB and Cambrex Profarmaco Milano S.r.l.

Insider Buying and Selling by Quarter for Cambrex (NYSE:CBM)

Receive News & Ratings for Cambrex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cambrex and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply